Neurocrine: Additional Phase 3 Data for Huntington Disease

 Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a leading neuroscience-focused biopharmaceutical company, today reported additional results from the Phase 3 KINECT-HD study investigating valbenazine for the treatment of chorea associated with Huntington Disease (HD). In December 2021, Neurocrine previously reported that once-daily administration of valbenazine was well tolerated with a statistically significant improvement in chorea associated with HD compared with placebo, along with substantial clinician- and patient-rated global improvement. The additional data includes an exploratory analysis of valbenazine effects over time, dosages at the end of the study, and detailed information about treatment-emergent adverse events (TEAEs) and safety parameters, such as electrocardiogram (ECG) and laboratory tests. These data (Poster #2: Valbenazine for the Treatment of Chorea Associated with Huntington Disease: Results from a Phase 3 Trial) will be shared at the 29^th annual meeting of the Huntington Study Group in Tampa, Florida on November 3–5.

https://www.biospace.com/article/releases/neurocrine-biosciences-presents-additional-phase-3-data-for-kinect-hd-study-evaluating-valbenazine-for-chorea-associated-with-huntington-disease-at-hsg-2022/